<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00699504</url>
  </required_header>
  <id_info>
    <org_study_id>TMC CAN 08 01</org_study_id>
    <nct_id>NCT00699504</nct_id>
  </id_info>
  <brief_title>Assess the Effect of Cangrelor at the Therapeutic Dose and a Supratherapeutic Dose Level on the QT/QTc Interval in Healthy Volunteers</brief_title>
  <official_title>A Double Blind, Placebo Controlled, Positive Controlled, Randomized, Crossover Study to Assess the Effect of Cangrelor at the Therapeutic Dose and a Supratherapeutic Dose Level on the QT/QTc Interval in Healthy Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The Medicines Company</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>The Medicines Company</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To assess the safety of cangrelor on cardiac repolarization as measured by electrocardiogram&#xD;
      (ECG) at therapeutic and supratherapeutic doses.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>June 2008</start_date>
  <completion_date type="Actual">November 2008</completion_date>
  <primary_completion_date type="Actual">November 2008</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change from baseline in placebo adjusted QTc with the individual correction method (QTcI) following cangrelor administration.</measure>
    <time_frame>Baseline to treatment</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Plasma concentrations of study drug and metabolite</measure>
    <time_frame>Baseline to treatment</time_frame>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Actual">67</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Lead in Phase</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Supratherapeutic dose of cangrelor</description>
  </arm_group>
  <arm_group>
    <arm_group_label>A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>therapeutic dose cangrelor treatment</description>
  </arm_group>
  <arm_group>
    <arm_group_label>B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>supratherapeutic dose cangrelor treatment</description>
  </arm_group>
  <arm_group>
    <arm_group_label>C</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>active comparator treatment</description>
  </arm_group>
  <arm_group>
    <arm_group_label>D</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>placebo treatment</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cangrelor</intervention_name>
    <description>IV bolus 60 mcg/kg; 8 mcg/kg x 3 hrs</description>
    <arm_group_label>Lead in Phase</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cangrelor</intervention_name>
    <description>30 mcg/kg bolus; 4 mcg/kg/min x 3 hrs. Oral placebo capsule</description>
    <arm_group_label>A</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cangrelor</intervention_name>
    <description>60 mcg/kg bolus; 8 mcg/kg/min x 3 hrs. Oral placebo capsule</description>
    <arm_group_label>B</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>moxifloxacin</intervention_name>
    <description>400 mg orally. Placebo IV bolus and infusion.</description>
    <arm_group_label>C</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>placebo IV and oral</description>
    <arm_group_label>D</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Male or non pregnant female between 18 years and 45 years of age, inclusive.&#xD;
&#xD;
          2. Female subjects of childbearing potential (ie, who have not undergone a hysterectomy,&#xD;
             have not had a tubal ligation, have not been postmenopausal for at least 12&#xD;
             consecutive months, or whose partner has not undergone a vasectomy) must commit either&#xD;
             to abstain continuously from heterosexual sexual contact or to use two methods of&#xD;
             birth control, one of which must be a barrier method (eg, hormonal contraception,&#xD;
             latex condom, diaphragm, or cervical cap), beginning at screening and throughout study&#xD;
             participation.&#xD;
&#xD;
          3. A body mass index (BMI) of 19 kg/m2 to 28 kg/m2, inclusive.&#xD;
&#xD;
          4. Agrees to abstain from alcohol consumption for at least 3 days before first dosing&#xD;
             with study drug and throughout study participation.&#xD;
&#xD;
          5. Agrees to abstain from caffeine and nicotine replacement therapy during the days of&#xD;
             study drug administration and serial ECG measurements.&#xD;
&#xD;
          6. No clinically significant abnormal findings on the physical examination, ECG, blood&#xD;
             pressure, heart rate, medical history, or clinical laboratory tests during screening.&#xD;
&#xD;
          7. Serum magnesium and potassium levels within the normal range per the local lab at the&#xD;
             time of screening.&#xD;
&#xD;
          8. Healthy volunteer as determined by the screening assessments.&#xD;
&#xD;
          9. Willing and able to comply with all trial requirements.&#xD;
&#xD;
         10. Provide written informed consent before initiation of any study related procedures.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Known or suspected pregnancy.&#xD;
&#xD;
          2. Increased bleeding risk: ischemic stroke within the last year or any previous&#xD;
             hemorrhagic stroke, tumor, or intracranial aneurysm; recent (&lt;1 month) trauma or major&#xD;
             surgery; active bleeding.&#xD;
&#xD;
          3. Impaired hemostasis: known International Normalized Ratio (INR) &gt;1.5; past or present&#xD;
             bleeding disorder (including congenital bleeding disorders such as von Willebrand's&#xD;
             disease or hemophilia, acquired bleeding disorders, and unexplained clinically&#xD;
             significant bleeding disorders), thrombocytopenia (platelet count &lt;100,000/ÂµL).&#xD;
&#xD;
          4. Sustained supine systolic blood pressure &gt;140 mmHg or &lt;100 mmHg or a diastolic blood&#xD;
             pressure &gt;95 mmHg or &lt;60 mmHg at screening or baseline. Blood pressure may be retested&#xD;
             twice in the supine position at intervals of 5 minutes. Blood pressure is considered&#xD;
             sustained if either the systolic or the diastolic pressure exceeds the stated limits&#xD;
             after three assessments.&#xD;
&#xD;
          5. Resting pulse rate of &lt;50 beats per minute (bpm) or &gt;100 bpm.&#xD;
&#xD;
          6. Abnormality in the 12 lead ECG that, in the opinion of the investigator, increases the&#xD;
             risk of participating in the study, such as a corrected QT interval (QTcB or QTcF)&#xD;
             &gt;450 milliseconds. The following conduction abnormalities may confound QTc analysis&#xD;
             and should be avoided: PR &gt;220 milliseconds, second or third degree atrioventricular&#xD;
             (AV) block, intraventricular conduction defect (IVCD) with QRS &gt;120 milliseconds,&#xD;
             complete left bundle branch block (LBBB), left anterior fascicular block (LAFB), left&#xD;
             posterior fascicular block (LPFB), right bundle branch block (RBBB), or Wolff&#xD;
             Parkinson White syndrome (WPW) (WPW defined as PR &gt;120 milliseconds, P axis from 1 to&#xD;
             90, QRS complex &gt;120 milliseconds, delta wave present).&#xD;
&#xD;
          7. Personal history of long QT syndrome, heart failure, or hypokalemia.&#xD;
&#xD;
          8. Personal history of unexplained syncope.&#xD;
&#xD;
          9. Immediate-family history of long QT syndrome.&#xD;
&#xD;
         10. Family history of sudden death.&#xD;
&#xD;
         11. Concurrent medical conditions, therapy, or medications that affect the ECG, especially&#xD;
             prolongation of the QT/QTc interval.&#xD;
&#xD;
         12. Use of prescription or over the counter (such as pseudoephedrine containing cold&#xD;
             medicines) medication, including herbal remedies and health supplements, known to&#xD;
             prolong the QT/QTc interval within 14 days prior to start of the study and throughout&#xD;
             study participation.&#xD;
&#xD;
         13. Intention to use prescription (other than thyroid hormone replacement if the dose and&#xD;
             regimen of such replacement therapy has been stable for at least 4 weeks prior to&#xD;
             screening and is expected to remain stable during study participation or hormonal&#xD;
             contraception) or over the counter medication, including herbal remedies and health&#xD;
             supplements, within 14 days before the initial dose of study drug and throughout study&#xD;
             participation. If this situation arises, inclusion of an otherwise suitable volunteer&#xD;
             may be at the discretion of the investigator in discussion with the Sponsor.&#xD;
&#xD;
         14. Current smokers or subjects who have discontinued smoking fewer than 6 months prior to&#xD;
             study entry.&#xD;
&#xD;
         15. Donation of any blood or plasma in the last month, or donation of &gt;400 mL of blood&#xD;
             within the 3 months preceding study drug administration.&#xD;
&#xD;
         16. Clinically significant abnormalities in clinical laboratory test results.&#xD;
&#xD;
         17. Positive virology screen for human immunodeficiency virus (HIV), hepatitis B, or&#xD;
             hepatitis C.&#xD;
&#xD;
         18. Positive urine test for drugs of abuse or alcohol.&#xD;
&#xD;
         19. Clinically significant disease or condition affecting a major organ system, including,&#xD;
             but not limited to, gastrointestinal, renal, hepatic, bronchopulmonary, neurological,&#xD;
             metabolic or cardiovascular disease.&#xD;
&#xD;
         20. Allergy, hypersensitivity, or contraindication to quinolone antibiotics, cangrelor, or&#xD;
             any of their excipients.&#xD;
&#xD;
         21. History of multiple adverse drug allergies of any origin.&#xD;
&#xD;
         22. Deemed by the investigator, for any reason, to be inappropriate for this study,&#xD;
             including subjects who are unable to communicate or to cooperate with the&#xD;
             investigator.&#xD;
&#xD;
         23. Treatment with other investigational agents or devices within the 30 days preceding&#xD;
             randomization, planned use of other investigational drugs or devices during study&#xD;
             participation, or previous enrollment in this trial.&#xD;
&#xD;
         24. Inability to give informed consent or high likelihood of being unable to complete the&#xD;
             necessary confinement.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Charles River Clinical Services NW</name>
      <address>
        <city>Tacoma</city>
        <state>Washington</state>
        <zip>98418</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2012</verification_date>
  <study_first_submitted>June 13, 2008</study_first_submitted>
  <study_first_submitted_qc>June 17, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 18, 2008</study_first_posted>
  <last_update_submitted>January 13, 2012</last_update_submitted>
  <last_update_submitted_qc>January 13, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 18, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>ECG</keyword>
  <keyword>QT</keyword>
  <keyword>Effect of study drug on healthy volunteers</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Moxifloxacin</mesh_term>
    <mesh_term>Cangrelor</mesh_term>
  </intervention_browse>
  <pending_results>
    <submitted>April 23, 2013</submitted>
    <returned>June 14, 2013</returned>
    <submitted>May 14, 2015</submitted>
    <returned>June 1, 2015</returned>
  </pending_results>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

